Repligen Aktie
WKN: 870980 / ISIN: US7599161095
|
30.10.2026 11:35:51
|
Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity
(RTTNews) - Repligen Corp. (RGEN), a bioprocessing company, on Friday announced agreements to issue $1 billion in 0.25% convertible senior notes due 2031.
The transactions are expected to close on or about November 6.
Of the new notes, $541.4 million will be exchanged for $456.8 million of existing 1.00% notes due 2028, while $458.6 million will be issued for cash.
The new notes will have an initial conversion price of $226.37 per share, representing a 20% premium over the October 29 closing price.
The company expects $458.6 million in gross cash proceeds. It plans to use approximately $120 million to repurchase shares from certain note purchasers at $188.64 per share through a financial intermediary.
The remaining proceeds will be used for working capital, general corporate purposes and potential acquisitions or investments in complementary businesses, products, services and technologies.
Following the transactions, approximately $143.2 million of the existing 2028 notes will remain outstanding under their current terms.
The company said it will receive no cash from the exchange transactions.
The company said the deal will extend debt maturity, reduce interest expenses and improve financial flexibility.
Lower interest costs are expected to provide a small benefit to adjusted earnings per share in 2026, with additional benefits in 2027.
The placement agent intends to purchase approximately $30 million of its shares from certain transaction participants at a discount to the October 29 closing price.
On Thursday, Repligen Corp closed trading 2.14% higher at $188.64 on the Nasdaq.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Repligen Corp.
Analysen zu Repligen Corp.
Aktien in diesem Artikel
| Repligen Corp. | 148,85 | -4,15% |
|